When were the SUPN Performance Share Units originally awarded to the CFO?

According to the footnote, the Performance Share Units were originally awarded on February 19, 2025 . A portion vested upon achievement of individual performance objectives within a defined performance period, with those objectives established on May 3, 2025 .

What were the vesting conditions for the SUPN Performance Share Units granted to the CFO?

The grant vested based on individual performance objectives within a defined performance period . The filing states that these objectives were established on May 3, 2025 , and that a portion of the February 19, 2025 award vested upon achieving those objectives.

Supernus Pharmaceuticals (SUPN) CFO awarded 1,250 performance share units tied to stock

Q: What insider transaction did SUPN report for Timothy C. Dec?

SUPERNUS PHARMACEUTICALS, INC. reported that CFO Timothy C. Dec acquired 1,250 Performance Share Units on July 29, 2026. These units correspond to 1,250 shares of common stock now held directly at a grant price of $0.00 per unit.

Q: How many shares are involved in Timothy C. Dec’s latest SUPN Form 4?

The filing shows 1,250 Performance Share Units , each tied to one share of common stock . Following this award, Timothy C. Dec directly holds 1,250 units and an equivalent number of underlying common shares related to this grant.

Q: What type of security did SUPN’s CFO receive in this Form 4 filing?

The CFO received Performance Share Units that are derivatives linked to common stock . The reported transaction covers 1,250 units , representing the right to receive 1,250 shares of common stock subject to the plan’s terms and conditions.

Q: Does the SUPN Form 4 indicate any sale of shares by the CFO?

No, the Form 4 reports only an acquisition of 1,250 Performance Share Units by the CFO. The transaction code is A , described as a grant, award, or other acquisition, with no reported sales or dispositions in this filing.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. reported that Senior Vice-President & CFO Timothy C. Dec acquired 1,250 Performance Share Units on July 29, 2026, representing 1,250 shares of common stock held directly at a per-unit price of $0.00. These units were originally awarded on February 19, 2025, with a portion vesting upon achievement of individual performance objectives set within a defined performance period and established on May 3, 2025.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider DEC TIMOTHY C

Role Senior Vice-President & CFO

Type	Security	Shares	Price	Value
Grant/Award	Performance Share Unit ^F1	1,250	$0.00	$0.00

Holdings After Transaction: Performance Share Unit — 1,250 shares (Direct)

Footnotes (1)

F1. On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Key Figures

Performance Share Units granted: 1,250 units Transaction price per unit: $0.00 Units held after transaction: 1,250 units +3 more

6 metrics

Performance Share Units granted 1,250 units Grant/award acquisition reported on July 29, 2026

Transaction price per unit $0.00 Grant of 1,250 Performance Share Units to CFO

Units held after transaction 1,250 units Total Performance Share Units directly held by CFO following the award

Underlying common stock 1,250 shares Common stock underlying the granted Performance Share Units

Original award date February 19, 2025 Date the Performance Share Units were first awarded

Objectives established May 3, 2025 Date individual performance objectives for vesting were established

Key Terms

Performance Share Units, defined performance period, individual performance objectives

3 terms

defined performance period financial

"objectives within a defined performance period, which objectives were established"

individual performance objectives financial

"vested upon the achievement of individual performance objectives within a defined"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/31/2026 - 05:06 PM Accepted by SEC EDGAR 07/31/2026 - 05:05 PM

FAQ

What insider transaction did SUPN report for Timothy C. Dec?

SUPERNUS PHARMACEUTICALS, INC. reported that CFO Timothy C. Dec acquired 1,250 Performance Share Units on July 29, 2026. These units correspond to 1,250 shares of common stock now held directly at a grant price of $0.00 per unit.

How many shares are involved in Timothy C. Dec’s latest SUPN Form 4?

The filing shows 1,250 Performance Share Units, each tied to one share of common stock. Following this award, Timothy C. Dec directly holds 1,250 units and an equivalent number of underlying common shares related to this grant.

What type of security did SUPN’s CFO receive in this Form 4 filing?

The CFO received Performance Share Units that are derivatives linked to common stock. The reported transaction covers 1,250 units, representing the right to receive 1,250 shares of common stock subject to the plan’s terms and conditions.

Does the SUPN Form 4 indicate any sale of shares by the CFO?

No, the Form 4 reports only an acquisition of 1,250 Performance Share Units by the CFO. The transaction code is A, described as a grant, award, or other acquisition, with no reported sales or dispositions in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DEC TIMOTHY C

(Last)

(First)

(Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.

9715 KEY WEST AVENUE

(Street)

ROCKVILLE

MARYLAND

20850

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Senior Vice-President & CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance Share Unit	$0	07/29/2026		A		1,250		⁽¹⁾	⁽¹⁾	Common Stock	1,250	$0	1,250	D

Explanation of Responses:

1. On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Remarks:

	/s/ Timothy C. Dec	07/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR